Fetal Growth Restriction a Case Control Study
ConditionIdiopathic Fetal Growth Restriction
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age19+
SponsorNational University of Malaysia
About this trial
The study aims to investigate the responsible factors that leads to idiopathic fetal growth restriction.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
singleton
dated pregnancy
Disqualifiers
fetus with structural or chromosomal anomaly
receive treatments such as aspirin, progestogen, low molecular weight heparin
has pre-existing medical disorders such as autoimmune disease, hypertension, diabetes
smoking
Trial population
Women diagnosed to have fetal growth restriction within 24 until 32 weeks gestation the absence of hypertension, diabetes or autoimmune disease.
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
58 Participants
are grouped into 1 trial groupGroup A: Women with pregnancies affected by idiopathic fetal growth restriction
Trial outcomes
Primary outcomes
1
Maternal serum level of progesterone
Maternal blood will be withdrawn and serum isolated. Measurement of progesterone level will be performed from the serum sample using ELISA.
Time frame
At the point of recruitment from 24 until 32 weeks gestation.2
Placental immunoexpression of Heme Oxygenase 1
Immunoexpression of Heme Oxygenase 1 in syncytiotrophoblasts, cytotrophoblasts, fetal endothelial cells, maternal vessels and decidual cells.
Time frame
At delivery within 24 until 38 weeks gestation.Secondary outcomes
1
Placenta histopathology examination
Placenta will be examined histopathologically
Time frame
At delivery within 24 until 38 weeks gestationSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov